Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.
Actively Recruiting
Randomized Study Comparing Partial Versus Whole Breast Irradiation in Women with Early Breast Cancer
Researchers are evaluating radiation treatments for women with small, node-negative invasive breast cancer measuring 3 cm or less. This trial compares partial breast irradiation PBI to whole breast irradiation WBI, both given once daily over about one week after breast-conserving surgery. The main goal is to see if PBI is not worse than WBI for preventing local cancer recurrence and if it improves cosmetic outcomes, as judged by patients, three years after treatment. Participants are randomly assigned to receive either PBI or WBI. Both groups receive a total radiation dose of 26 Gy split into five daily treatments over 5 to 7 days, with a possible extension to 8 days due to scheduling. The WBI targets the entire breast, while PBI focuses radiation on the tumor bed plus a margin of normal tissue. Patients are not informed which treatment they receive to avoid bias in assessing cosmetic results. Key factors such as tumor size, estrogen receptor status, and treatment center are used for group assignment. During the study, participants will be monitored annually for five years to assess local recurrence, distant disease-free survival, overall survival, and radiation side effects. Cosmetic outcomes will be evaluated by both patients and clinical staff at 3 and 5 years. Quality of life will also be measured at multiple time points. The study lasts several years, with primary outcomes assessed at three years and continued follow-up through at least five years post-treatment.
Actively Recruiting
Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.
Actively Recruiting
Researchers are evaluating TO-O-1007, a biodegradable sustained-release intravitreal implant, for the treatment of Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. The study is designed to assess the safety, tolerability, pharmacokinetics, and early effectiveness of this implant. TO-O-1007 aims to provide a long-lasting treatment option that may slow the progression of GA lesions and reduce the need for frequent eye injections. Participants will receive one of several treatments a low-dose or high-dose TO-O-1007 implant injected into the eye, or a sham injection to maintain masking. The implant gradually degrades, releasing medication over approximately six months. This study includes two phases Phase I and Phase IIa with different dosing groups to evaluate the implants effects and safety compared to a sham treatment. During the study, participants will undergo eye exams to monitor lesion growth and visual function at multiple time points, including baseline, 12 weeks, and 24 weeks. Safety will be closely watched through treatment-emergent adverse event recording up to six months. Pharmacokinetic sampling will be done at several intervals to measure drug exposure. The total study duration extends up to 28 weeks with regular visits for assessments and monitoring of the implants effects on vision and eye health.
Actively Recruiting
Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device. Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation. Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.
Actively Recruiting
Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.
Actively Recruiting
This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.
Actively Recruiting
Researchers are evaluating the drug ADX-038 in participants aged 60 years and older who have geographic atrophy GA secondary to age-related macular degeneration AMD. This Phase 2, randomized, masked, placebo-controlled study aims to compare the effects of ADX-038 with a placebo on preserving the ellipsoid zone EZ layer in the eye over 12 months. The trial will also assess the safety, pharmacokinetics, and pharmacodynamics of ADX-038. Participants will receive either subcutaneous injections of ADX-038, a siRNA duplex oligonucleotide, or a saline placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. The treatment is administered over a 12-month period, during which the impact on eye structure and function will be closely monitored. Throughout the study, participants will attend clinic visits for assessments, including high-quality fundus imaging and other study-related procedures. They must complete meningococcal and pneumococcal vaccinations as required by the protocol. Researchers will monitor the preservation of the EZ layer as the primary outcome to evaluate treatment effect, alongside safety and drug behavior in the body. The total study duration extends until August 2030, with primary outcome results expected by February 2030.
Actively Recruiting
This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.
1-10 of 11
1